or Try an Advanced Search...

    ETF Components for FLSW - Franklin FTSE Switzerland ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    NVS B -1.64 12.27
    ABBV D -4.58 3.89
    LOGI D 0.69 0.86

    Represented by ETF Holdings

    Keywords: Eye Care Products Pharmaceutical Active Pharmaceutical Ingredients Adalimumab Advanced Prostate Cancer Anemia Animal Health Antibiotics Atopic Dermatitis Audiovisual Autoimmune Disease Biotechnology Blood Cancers Blood Test Chronic Idiopathic Constipation Combination Drugs Communication Products Constipation Contact Lens Contact Lenses
    Industries: Drug Manufacturers - Major Computer Systems

    Recent News for Franklin FTSE Switzerland ETF & its Holdings

    Date Stock Title
    Apr 26 ABBV Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?
    Apr 26 NVS Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
    Apr 26 ABBV Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
    Apr 26 ABBV AbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates Despite Revenue Challenges
    Apr 26 ABBV AbbVie in charts: Q1 Skyrizi, Rinvoq sales jump, while revenue from Humira continues to fall
    Apr 26 ABBV AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title
    Apr 26 ABBV AbbVie lifts profit forecast after Skyrizi sales beat expectations
    Apr 26 ABBV AbbVie Non-GAAP EPS of $2.31 beats by $0.05, revenue of $12.31B beats by $370M
    Apr 26 ABBV AbbVie raises annual profit forecast on strong Skyrizi sales
    Apr 26 ABBV AbbVie Reports First-Quarter 2024 Financial Results
    Apr 26 ABBV PCE reading, Microsoft, Alphabet jump on earnings: Yahoo Finance
    Apr 25 ABBV Cigna to offer Humira rivals with $0 copay at specialty pharmacy
    Apr 25 ABBV AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
    Apr 25 ABBV AbbVie reports positive results from Rinvoq versus Dupixent study
    Apr 25 ABBV AbbVie Q1 Preview: Skyrizi and Rinvoq’s launches could help Q1
    Apr 25 LOGI Logitech (LOGI) to Report Q4 Earnings: What's in the Offing?
    Apr 25 ABBV UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
    Apr 25 ABBV Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
    Apr 25 NVS Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
    Apr 25 ABBV New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
    The investment seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the FTSE Switzerland RIC Capped Index (the FTSE Switzerland Capped Index). Under normal market conditions, the fund invests at least 80% of its assets in the component securities of the FTSE Switzerland Capped Index and in depositary receipts representing such securities. The FTSE Switzerland Capped Index is based on the FTSE Switzerland Index and is designed to measure the performance of Swiss large- and mid-capitalization stocks. The fund is non-diversified.
    Exchange Traded Fund ETF Stock Market Index Ftse 100 Index Ftse Group Index Numbers Switzerland Index
    Back to the Main FLSW Page...